Marshall Wace, LLP Cyma Bay Therapeutics, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $6.77 Million - $11 Million	-623,324 Reduced 79.74%	158,411 $2.36 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $4.02 Million - $5.9 Million	538,554 Added 221.46%	781,735 $8.56 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $949,037 - $1.55 Million	161,401 Added 197.36%	243,181 $2.12 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $263,331 - $512,760	81,780 New	81,780 $512,000
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $18,920 - $37,290	11,000 New	11,000 $33,000
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $384,713 - $868,625	-63,589 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$8.16 - $13.42 $75,324 - $123,880	9,231 Added 16.98%	63,589 $844,000
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $355,501 - $638,162	54,358 New	54,358 $428,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.